ArticleJournal of vascular surgery cases and innovative techniques2026
Reverse flow-controlled atherectomy treatment using the JETSTREAM atherectomy device for reducing distal embolization.
Article in Journal of vascular surgery cases and innovative techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severely calcified femoropopliteal lesions remain technically challenging, with distal embolization (DE) being a major concern during atherectomy. We developed a new method, the reverse flow-controlled atherectomy treatment (R-CAT), using the JETSTREAM system, to enhance embolic protection. By combining retrograde insertion of an occlusion catheter with distal flow arrest and aspiration, R-CAT enables safe atherectomy even in long, heavily calcified lesions with poor tibial runoff. In a representative case, both technical and procedural success were achieved without complications or DE. R-CAT is a feasible and safe approach for reducing DE and enhancing procedural safety in complex femoropopliteal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.